Ruchika Chitravanshi And Sohini Das

Stories by Ruchika Chitravanshi And Sohini Das

As Covid cases rise again, states impose restrictions

As Covid cases rise again, states impose restrictions

Rediff.com   26 Feb 2021

Here's what some states are doing to get a grip on the situation. Ruchika Chitravanshi & Aneesh Phadnis report

How the new Companies Act will affect Tata Sons, Bharti Telecom

How the new Companies Act will affect Tata Sons, Bharti Telecom

Rediff.com   22 Feb 2021

Companies such as Tata Sons and Bharti Telecom, which are unlisted but have listed subsidiaries, may soon have to file periodic financial statements with the registrar of companies under the new provision of the Companies Act. The provision requires greater financial disclosures by a certain category of unlisted companies.

Public may get COVID-19 vaccine by April

Public may get COVID-19 vaccine by April

Rediff.com   22 Feb 2021

Anybody over 50 years of age or with co-morbidities can get a date, place and time of choice for getting the vaccine shots.

Low turnout forces govt to mull private rollout of Covid vaccine

Low turnout forces govt to mull private rollout of Covid vaccine

Rediff.com   10 Feb 2021

Two weeks after the vaccination programme started, about 37 per cent of the targeted 10 million healthcare professionals had received the first shot. This slow rate may prompt the government to allow vaccines in the private market sooner, to use up the doses before they expire, Sohini Das reports.

After a year of Covid, India may not face a second wave

After a year of Covid, India may not face a second wave

Rediff.com   9 Feb 2021

Epidemiologists point out that if there is no second wave, it means that the number of infected has surpassed the uninfected, reports Ruchika Chitravanshi.

Lupin aims to enter Chinese market in the next one year

Lupin aims to enter Chinese market in the next one year

Rediff.com   8 Feb 2021

Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.

More Covid vaccine candidates get approval for clinical trials in India

More Covid vaccine candidates get approval for clinical trials in India

Rediff.com   6 Feb 2021

Ahmedabad-based Zydus Cadila, Bharat Biotech's intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.

More Indians will take vaccine if politicians do: Survey

More Indians will take vaccine if politicians do: Survey

Rediff.com   5 Feb 2021

In India, Opposition parties along with healthcare professionals have urged the government, including Prime Minister Narendra Modi and top leaders, to take either of the Covishield or Covaxin doses, which could help in drastically reducing trust and fear issues amongst citizens., reports Sohini Das.

Despite Covid, registration of new companies went up in 2020

Despite Covid, registration of new companies went up in 2020

Rediff.com   24 Jan 2021

Moreover, 5,611 companies struck off earlier by the ministry of corporate affairs because of compliance-related lacunae, were registered again.

Trusts, societies have to register with MCA by April 1

Trusts, societies have to register with MCA by April 1

Rediff.com   23 Jan 2021

Corporate social responsibility rules that kicked in on Friday also set a three year time-limit for any CSR project, among a series of other amendments introduced by the government.

Covaxin has tolerable safety: Lancet

Covaxin has tolerable safety: Lancet

Rediff.com   23 Jan 2021

The vaccine was well tolerated in all dose groups with no vaccine-related adverse events.

Budget 2021: Sharper focus on health care likely

Budget 2021: Sharper focus on health care likely

Rediff.com   20 Jan 2021

CII has also called for tax incentives for new health care projects and import duty relief for lifesaving equipment.

Why early applicant Pfizer's Covid vaccine is delayed

Why early applicant Pfizer's Covid vaccine is delayed

Rediff.com   19 Jan 2021

Pfizer sought to participate in the Subject Expert Committee consultations towards an emergency use authorisation for its Covid-19 vaccine. However, the company representatives have been unable to participate in the meetings because of extremely short notices of a few hours or less and time-zone limitations.

Serum Institute may supply 400 million doses to Gavi-Covax

Serum Institute may supply 400 million doses to Gavi-Covax

Rediff.com   19 Jan 2021

Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose.

Govt proposes phase-wise pre-packed insolvency process

Govt proposes phase-wise pre-packed insolvency process

Rediff.com   18 Jan 2021

A draft proposal by the sub-committee of the insolvency law committee has recommended that the corporate debtor (CD) may initiate the prepack since it may prove difficult to implement if creditors are allowed to do so without the willingness of the promoter.

V G Somani: The head of DCGI known as man of actions, not of words

V G Somani: The head of DCGI known as man of actions, not of words

Rediff.com   18 Jan 2021

'Safety is my first priority.' 'I need to ensure that any drug or vaccine that our citizens get is first safe.'

Serum Institute began its journey in a small lab in stud farm

Serum Institute began its journey in a small lab in stud farm

Rediff.com   16 Jan 2021

The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.

'Vaccine is far safer than getting Covid'

'Vaccine is far safer than getting Covid'

Rediff.com   16 Jan 2021

'I would go for Bharat Biotech's Covaxin and not Covishield, and that is my personal judgment since at least 11,500 have got at least one dose by now and it has proven to be safe.'

'It'll take 3-4 years to vaccinate 80% of population'

'It'll take 3-4 years to vaccinate 80% of population'

Rediff.com   11 Jan 2021

'We are hoping by March, the government allows us to export and give it to the private market.'

COVID-19 Vaccine: Vial, syringe makers ramp up

COVID-19 Vaccine: Vial, syringe makers ramp up

Rediff.com   2 Jan 2021

'The government should put the whole road map together for the vaccine and decide how industry can support...' 'They should allow the private sector to vaccinate.'